Supplementary data: Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Channeling effects in the prescription of </b><b>new therapies: the case of emicizumab for </b><b>hemophilia A</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplementary Table 1: </b>Code listings</li></ul><p><br></p>